DAFTAR PUSTAKA

[1] J. Lee *et al.*, "Current Status of Anti-Reflux Surgery as a Treatment for GERD," pp. 1–12, 2024.

[2] A. Widiyanto, S. A. Sartika, A. K. N. Utami, K. M. Dina, H. Anasulfalah, and T. S. H. Delimasari, "Edukasi GERD Untuk Generasi Gen Z: Strategi Peningkatan Pengetahuan dan Perubahan Perilaku Kesehatan," *J. Peduli Masy.*, vol. 6, no. 4, 2024.

[3] D. P. Sari, R. Rahardjoputro, and A. W. Amrullah, "Evaluasi Rasionalitas Penggunaan Obat GERD (Gastroesophageal Reflux Disease) Pada Pasien Dewasa Di Instalasi Rawat Inap RSUD Dr . Moewardi Surakarta Periode Tahun 2020-2023," vol. 12, no. 1, pp. 70–83, 2025.

[4] T. Kazakova, R. Danoff, I. Esteva, and A. Shchurin, "Gastro-esophageal reflux disease in primary care practice: a narrative review," *Ann. Esophagus*, vol. 6, pp. 1–11, 2023, doi: 10.21037/aoe-21-62.

[5] I. S. P. Radjamin, I. A. Nusi, and V. P. Kalajanti, "Profil Penderita Gastro Esophageal Reflux Disease (Gerd) Dan Non-Erosive Reflux Disease (Nerd) Di Rsud Dr. Soetomo Surabaya," *Biomorfologi*, vol. 29, no. 1, pp. 21–26, 2021.

[6] P. R. Muthmainnah, K. Syahril, Rahmawati, M. Nulanda, and A. S. Dewi, "Fakumi medical journal," *J. Mhs. Kedokt.*, vol. 2, no. 5, pp. 359–367, 2022.

[7] Sukirawati and Yusriyani, "Studi Interaksi Obat pada Pasiem Tukak Lambung di Rumah Sakit Umum Daerah I Lagagigo Kabupaten Luwu Timur," *J. Kesehat. Yamasi Makasar*, vol. 5, no. 2, pp. 121–127, 2021.

[8] A. P. Saraswati, E. Garianto, and Mulyarjo, "Hubungan antara Konsumsi Kopi dengan Gejala Gastroesophageal Reflux Disease (GERD)," *CoMPHI J. Community Med. Public Heal. Indones. J.*, vol. 1, no. 3, pp. 177–183, 2021.

[9] E. Susetyo *et al.*, "Profil Pengetahuan Mahasiswa Institut Teknologi Sepuluh NOpeber terhadap Penggunaan Obat Antasida," *J. Farm. Komunitas*, vol. 7, no. 2, pp. 48–55, 2020.

[10] Aprian Dwiatama and Fitrianti Darusman, "Kajian Pengobatan Tukak Lambung dan Gastroesophageal Reflux Disease (GERD)," *Bandung Conf. Ser. Pharm.*, vol. 2, no. 2, pp. 170–176, 2022, doi: 10.29313/bcsp.v2i2.3781.

[11] A. D. Kuswono, B. Yurizali, and R. R. Akbar, "Kejadian Gastroesophageal Reflux Disease (GERD) dengan GERD-Q pada Mahasiswa Kedokteran," *Baiturrahmah Med. J.*, vol. 1, no. 1, 2021, doi: 10.1007/978-3-319-44360-7_11.

[12] E. Sylvia and R. Suwahyu, "Hubungan Pola Makan dan Stress terhadap

Kejadian Gastritis di Ruang Rawat Inap Penyakit Dalam," *J. Ilm. Ners Indones.*, vol. 5, no. 1, pp. 44–50, 2024.

[13] N. Vetrivel, D. Praveen, P. R. Chowdary, K. E. Cheziyan, and M. V. Aanandhi, "Comparison of safety and effectiveness of ondansetron and domperidone in patients with gastrointestinal problems," vol. 10, no. 3, pp. 343–346, 2018.

[14] B. F. F. Ajjah, T. Mamfaluti, and T. R. I. Putra, "Hubungan Pola Makan Dengan Terjadinya Gastroesophageal Reflux Disease (Gerd)," *J. Nutr. Coll.*, vol. 9, no. 3, pp. 169–179, 2020, doi: 10.14710/jnc.v9i3.27465.

[15] E. M. Yamasaki T, Hemond C, "The changing epidemiology of gastroesophageal reflux disease: Are patients getting younger?," *J Neurogastroenterol Motil*, vol. 24, no. 4, pp. 559–69, 2018.

[16] J. E. Richter and J. H. Rubenstein, "Presentation and Epidemiology of Gastroesophageal Reflux Disease," *Gastroenterology*, vol. 154, no. 2, pp. 267–276, 2018, doi: 10.1053/j.gastro.2017.07.045.

[17] et al. Rafsanjani I, Fajrin Hanifa S, Hanif Mustofa D, "Imaging Pada Gastroesogafagial Reflux Disease Imaging on Gastroesofagial Refluxisease.," *Publ Ilm. Publ. online*, vol. 1563–1570, 2021.

[18] L. J. T. Ness-Jensen E, "smoking, alcohol consumption and gastro-oesophageal reflux disease.," *Best Pr. Res Clin Gastroenterol.*, vol. 31, no. 5, pp. 501–508, 2017.

[19] T. A., "Risk factors for gastroesophageal reflux disease symptoms related to lifestyle and diet.," *Rocz Panstw Zakl Hig.*, vol. 72, no. 1, pp. 21–28, 2021.

[20] B. F. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M and F. AC., "Global Prevalence of, and Risk Factors For, Gastro-oesophageal Reflux Symptoms: A Meta-analysis.," *Gut*, vol. 67, no. 3, pp. 430–40.

[21] Z. Mungan and B. P. Şimşek, "Which drugs are risk factors for the development of gastroesophageal reflux disease?," *Turkish J. Gastroenterol.*, vol. 28, no. Suppl 1, pp. S38–S43, 2017, doi: 10.5152/tjg.2017.11.

[22] J. Tack and J. E. Pandolfino, "Pathophysiology of Gastroesophageal Reflux Disease," *Gastroenterology*, vol. 154, no. 2, pp. 277–288, 2018, doi: 10.1053/j.gastro.2017.09.047.

[23] hafizh muhammad. Salim, "Hubungan Gastroesophageal Reflux Disease Dengan Kualitas Tidur Pada Mahasiswa Fakultas Kedokteran Universitas Muhammadiyah Sumatera Utara.," vol. 6, 2021.

[24] D. M. Hafizh S, "Hubungan Gastroesophageal Reflux Disease Dengan Kualitas Tidur Pada Mahasiswa Fakultas Kedokteran Universitas Muhammadiyah Sumatera Utara.," *J Ilm Maksitek*, vol. 6, no. 2, pp. 29–33, 2021.

[25] H. Pebriana, P., Puspitaningtyas, P. H., & Sasongko, "Penilaian pola

penggunaan obat berdasarkan indikator pereseoan WHO di RSUD Ir Soekarno Sukoharjo.," pp. 23–30, 2018.
[26] K. RI, *Profil Kesehatan Indonesia 2020*. Jakarta: Kemenkes RI, 2020.
[27] C. K. Rachman, "Evaluasi Penggunaan Obat Golongan Proton Pump Inhibittor (Ppi) Di Rs Pku Muhammadiyah Gamping. Yogyakarta, Universitas Islam Indonesia," 6AD.
[28] K. RI, *Profil Kesehatan Indonesia 2019*. Jakarta: Kemenkes RI, 2019.
[29] N. Allahham *et al.*, "Selective laser sintering 3D printing of orally disintegrating printlets containing ondansetron," *Pharmaceutics*, vol. 12, no. 2, pp. 1–13, 2020, doi: 10.3390/pharmaceutics12020110.
[30] S. S. Jana, M. D. Lad, S. Subramanian, and D. P. Sanap, "Ondansetron: A selective 5HT3 receptor antagonist and it advances in drug delivery system," *World J. Adv. Res. Rev.*, vol. 16, no. 3, pp. 068–077, 2022, doi: 10.30574/wjarr.2022.16.3.1275.
[31] K. M. Jannah and D. Firmanda, "Perbandingan Ondansetron dan Ranitidin untuk Hilangkan Rasa Mual Muntah Post Operasi di Rumah Sakit Yosua Lubuk Pakam Tahun 2021," *J. Kedokt. Ibnu Nafis*, vol. 11, no. 2, p. 88, 2022.
[32] A. F. Ariyani, A. Purnamayanti, and A. Kirtishanti, "Efektivitas Ondansetron sebagai Profilaksis Mual dan Muntah pada Pasien Kanker Payudara Stadium 3," vol. 7, no. 1, pp. 41–45, 2022, doi: 10.18860/jip.v7i1.16697.
[33] A. Hakamifard, A. Aria, and M. Momenzadeh, "Journal of Research in Pharmacy PracSevere Ondansetron-associated Hypokalemia in a Patient Diagnosed with Aspiration Pneumoniatice," *J. Res. Pharm. Pract.*, vol. 11, no. 2, 2022, doi: 10.4103/jrpp.jrpp.
[34] M. Heckroth, R. T. Luckett, C. Moser, D. Parajuli, and T. L. Abell, *Nausea and Vomiting in 2021 : A Comprehensive Update*, vol. 55, no. 4. 2022. doi: 10.1097/MCG.0000000000001485.Nausea.
[35] S. Shaveta, C. Diksha, and J. K. Upendra, "short review on domperidone tablet," vol. 5, no. 2348, pp. 14–19, 2017.
[36] S. Kay, "Domperidone: Mechanism of Action and Clinical Uses," *J. Diabet. Complicat. Med.*, vol. 09, no. 03, pp. 10–11, 2024, doi: 10.37421/2475-3211.2024.9.271.
[37] N. D. Kumalasari, W. D. Rahmawati, and D. B. Legowo, "Pengaruh Perbandingan Konsentrasi Crospovidone Dengan Amilum Oryzae Sebagai Bahan Penghancur Pada Oral Fast Dissolving Tablet Domperidone Base," *J. Farm. Indones.*, vol. 1, no. 2, pp. 11–20, 2020.
[38] Novi, A. Siswanto, and W. S. Rahayu, "Optimasi Formula Fast Disintegrating Tablet Domperidone Kombinasi Filler Binder Starch 1500 , Manitol dan Avicel PH 102 dengan Simple Lattice Design Optimization of Formulation Fast Disintegrating Tablet Domperidone Combination Filler

Agus Siswanto," *Pharm. J. Indones.*, vol. 21, no. 01, 2024.
[39] S. G. Situ, S. Bhuia, R. Chowdhury, and A. Hasan, "Synergistic Antiemetic Effects of Nerolidol on Domperidone, Hyoscine, and Ondansetron : In Vivo and in Silico Investigations on Receptor Binding Affinity," *Eur. Chem. Soc. Publ.*, vol. 202400345, no. 14, 2025, doi: 10.1002/open.202400345.
[40] A. Mahdaniyati, "Mekanisme Serotonin pada Saluran Pencernaan: A Systematic Review," *J. Heal. Res.*, vol. 5, no. 1, pp. 70–80, 2024.
[41] N. Kurniawati, F. X. Lameng, and A. Nasir, "Tinjauan mual dan muntah: etiologi, patofisiologi, dan pemilihan antiemetik pada berbagai kondisi klinis," *J. Penelit. Ilmu Kesehat. dan Farm.*, vol. 2, no. 1, pp. 40–69, 2025.
[42] M. Ahmad, A. Rawat, S. Farrukh, I. Haq, and A. K. Mandal, "Comparative Analysis of Oral Ondansetron , Metoclopramide , and Domperidone for Managing Vomiting in Children With Acute Gastroenteritis," vol. 15, no. 10, 2023, doi: 10.7759/cureus.47611.
[43] M. Siregar, C. Wiedyaningsih, and R. Mutiara, "Indonesian Journal of Pharmacology and Therapy Comparison ondansetron and domperidon as antiemetic for gastroenteritis in children : a review," vol. 5, no. 2, pp. 154–164, 2024.
[44] S. Rerksuppaphol and L. Rerksuppaphol, "Randomized Study of Ondansetron Versus Domperidone in the Treatment of Children With Acute Gastroenteritis," *J Clin Med Res*, vol. 5, no. 6, pp. 460–466, 2013.
[45] F. Ahmad, A. Farhat, N. Butt, M. A. Sadiq, and A. Rafiq, "Ondansetron vs Domperidone in the Treatment of Vomiting in Children with Acute Diarrhea : A Randomized , Double-Blind Study," vol. 16, no. 01, pp. 944–947, 2022.
[46] Sandu dan Muhammad Ali, "Dasar Metodologi Penelitian," no. June 2015, 2015.
[47] A. Rachman, H. Purnomo, and A. I. Samanlangi, *Metode Penelitian Kuantitatif, Kualitatif, Dan R & D*, vol. 11, no. 1. 2024. [Online]. Available: http://scioteca.caf.com/bitstream/handle/123456789/1091/RED2017-Eng-8ene.pdf?sequence=12&isAllowed=y%0Ahttp://dx.doi.org/10.1016/j.regsciurbeco.2008.06.005%0Ahttps://www.researchgate.net/publication/305320484_SISTEM_PEMBETUNGAN_TERPUSAT_STRATEGI_MELESTARI
[48] S. H. Sahir, *Metodologi Penelitian*. 2022.
[49] L. Harlina, P. Srikandi, and K. A. Kusumawati, "Pengaruh Store Atmosphere terhadap Keputusan Pembelian dan Kepuasan Pelanggan," *J. Adm. Bisnis*, vol. 15, no. 2, pp. 1–9, 2017.
[50] Asrulla, Risnita, M. S. Jailani, and F. Jeka, "Populasi dan Sampling (Kuantitatif), Serta Pemilihan Informan Kunci (Kualitatif) dalam Pendekatan Praktis," *J. Pendidik. Tambusai*, vol. 7, no. 3, pp. 26320–26332, 2023.

[51] I. M. Inadjo, B. J. Mokalu, and N. Kandowangko, "Adaptasi Sosial SDN 1 Pineleng Menghadapi Dampak Covid-19 Di Desa Pineleng 1 Kecamatan Pineleng Kabupaten Minahasa," *J. Ilm. Soc.*, vol. 3, no. 1, pp. 1–7, 2023, [Online]. Available: https://journal.unpas.ac.id/index.php/pendas/article/view/8077

[52] R. Akbar, U. S. Sukmawati, and K. Katsirin, "Analisis Data Penelitian Kuantitatif," *J. Pelita Nusant.*, vol. 1, no. 3, pp. 430–448, 2024, doi: 10.59996/jurnalpelitanusantara.v1i3.350.

[53] J. Amuthavalli Thiyagarajan *et al.*, "The un Decade of healthy ageing: Strengthening measurement for monitoring health and wellbeing of older people," *Age Ageing*, vol. 51, no. 7, pp. 1–5, 2022, doi: 10.1093/ageing/afac147.

[54] L. Mo *et al.*, "Global, regional, and national burden of gastroesophageal reflux disease (1990–2021): age-period-cohort analysis and Bayesian projections," *Front. Public Heal.*, vol. 13, no. July, 2025, doi: 10.3389/fpubh.2025.1576527.

[55] S. Ndraha, G. A. Harefa, and B. Khumar, "Hubungan Gaya Hidup Terhadap Kejadian GERD (Gastroesophageal Reflux Disease) di RSUD Koja Jakarta Utara," *J. MedScientiae*, vol. 2, no. 3, pp. 341–346, 2023, doi: 10.36452/jmedscientiae.v2i3.2909.

[56] E. S. Visnes *et al.*, "Prevalence and risk factors of gastro-oesophageal reflux symptoms among adolescents, the HUNT study," *Scand. J. Gastroenterol.*, vol. 59, no. 7, pp. 816–820, 2024, doi: 10.1080/00365521.2024.2349646.

[57] N. F. Zamani, A. S. Sjahid, T. H. Tuan Kamauzaman, Y. Y. Lee, and M. A. Islam, "Efficacy and Safety of Domperidone in Combination with Proton Pump Inhibitors in Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials," *J. Clin. Med.*, vol. 11, no. 18, 2022, doi: 10.3390/jcm11185268.

[58] B. Ye, Y. Wang, L. Lin, L. Jiang, and M. Wang, "Sex-Based Differences in pH Parameters and Esophageal Impedance of Patients With Gastroesophageal Reflux Disease," *Front. Med.*, vol. 8, no. May, pp. 1–9, 2021, doi: 10.3389/fmed.2021.629302.

[59] A. M. Ashour, "The preventive effects of ondansetron on chemotherapy-induced nausea and vomiting in adult cancer patients: systematic review from ClinicalTrials.gov," *Front. Pharmacol.*, vol. 14, no. November, pp. 1–6, 2023, doi: 10.3389/fphar.2023.1310455.

[60] K. Peprah and S. McCormack, *Ondansetron in patients requiring anti-emetics : a review of clinical effectiveness, cost-effectiveness, and guidelines*, Version: 1. Canada: Ottawa : Canadian Agency for Drugs and Technologies in Health 2020, 2020.

[61] Q. Qi, N. Wang, H. Liu, and Y. Li, “Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis,” *BMC Gastroenterol.*, vol. 23, no. 1, pp. 1–10, 2023, doi: 10.1186/s12876-023-03014-9.

[62] P. O. Katz, K. B. Dunbar, F. H. Schnoll-Sussman, K. B. Greer, R. Yadlapati, and S. J. Spechler, *ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease*, vol. 117, no. 1. 2022. doi: 10.14309/ajg.0000000000001538.

[63] D. H. Jung, C. W. Huh, S. K. Lee, J. C. Park, S. K. Shin, and Y. C. Lee, “A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease,” *J. Neurogastroenterol. Motil.*, vol. 27, no. 2, pp. 165–175, Apr. 2021, doi: 10.5056/jnm20161.

[64] C. Akman, B. Ozkaya, S. Dehmen, and O. Karcioglu, “Use of Antiemetic Agents and Other Symptomatic Treatment of Abdominal Conditions: Which are the best?,” *Curr. Pharm. Des.*, vol. 32, Jun. 2026, doi: 10.2174/0113816128445194260508053015.

[65] J. Herrstedt *et al.*, “2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting,” *ESMO Open*, vol. 9, no. 2, p. 102195, Feb. 2024, doi: 10.1016/j.esmoop.2023.102195.

[66] A. Ghamar-Shooshtari *et al.*, “Polypharmacy and pattern of medication use among patients with gastroesophageal reflux disease: results from Pars Cohort study,” *BMC Gastroenterol.*, vol. 23, no. 1, pp. 1–9, 2023, doi: 10.1186/s12876-023-03086-7.

[67] R. Patala, J. Tandi, and N. Ulzmi, “Rasionalitas Penggunanaan Obat Pada . Pasien GERD Di Instalasi Rawat Inap Rumah Sakit Umum Anutapura Palu,” pp. 62–73, 2021, doi: 10.20961/jpscr.v6i1.43170.

[68] Z. Tang, J. Ling, and X. Tang, “Gastroesophageal Reflux Disease Incidence in Adolescents and Young Adults Aged 10–24 Years: Results from the Global Burden of Disease Study,” *Dig. Dis. Sci.*, vol. 71, no. 3, pp. 1015–1028, Mar. 2026, doi: 10.1007/s10620-025-09446-5.